SCHEMBL560202

SCHEMBL560202

Cc1ccc(C[Mg]Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.48
CYP2A6 P11509 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
IDO1 P14902 2/20 0.46
ACHE P22303 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
AGXT P21549 2/20 0.41
TP53 P04637 1/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
SRD5A2 P31213 1/20 0.36
TSHR P16473 1/20 0.36
CHRM2 P08172 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7987789 0.93 CYP1A2 (0.43) CYP1A2CYP2A6TAAR1IDO1ACHE
SCHEMBL558967 0.79 TAAR1 (0.48) CYP1A2CYP2A6TAAR1IDO1TDP1
SCHEMBL1141849 0.76 TAAR1 (0.50) CYP2A6TAAR1IDO1AGXTALDH1A1
SCHEMBL5953553 0.75 LPL (0.45) TAAR1ALDH1A1POLB
SCHEMBL5954137 0.75 BCHE (0.47) CYP1A2ACHETP53LMNAPOLB
SCHEMBL2291118 0.74 ALDH1A1 (0.35) TAAR1MAPTALDH1A1LMNACYP11B1
SCHEMBL5249994 0.74 IDO1 (0.46) CYP1A2CYP2A6TAAR1IDO1ACHE
SCHEMBL5633593 0.74 IDO1 (0.46) CYP1A2CYP2A6TAAR1IDO1ACHE
SCHEMBL467216 0.73 TAAR1 (0.54) TAAR1IDO1AGXTTP53MAPT
SCHEMBL1006697 0.73 CYP1A2 (0.37) CYP1A2MAPTALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 WO claimed
US-7273948-B2 Process of preparing esters and ethers of probucol and derivatives thereof ATHEROGENICS, INC. (US) 2007-09-25 US claimed
EP-1594824-A4 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF ATHEROGENICS INC (US) 2007-04-04 EP claimed
EP-1594824-A2 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF Atherogenics, Inc. (US) 2005-11-16 EP claimed
US-20040204485-A1 Process of preparing esters and ethers of probucol and derivatives thereof CRABTREE ACQUISITION CO, LLC 2004-10-14 US claimed
WO-2004062622-A2 PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF ATHEROGENICS, INC. (US) 2004-07-29 WO claimed
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 WO disclosed
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 US disclosed
CN-118527068-A Tubular reactor capable of continuously producing Grignard reagent 吉林化工学院 2024-08-23 CN disclosed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 US disclosed
CN-112789108-B Catalyst for asymmetric hydrogenation of compounds containing carbon double bonds 格拉斯如睦株式会社 2023-09-19 CN disclosed
US-5190957-A TREATMENT OF MULTI-DRUG RESISTANT TUMORS WITH QUINOLYL-AND ISOQUINOLYLOXAZOLE-2-ONES MERRELL DOW PHARMACEUTICALS INC. (US) 1993-03-02 US disclosed
WO-1991018007-A1 PHTHALOCYANATOPOLYETHYLENE GLYCOL, AND PHTHALOCYANATO SACCHARIDES AS FLUORESCENT DIGOXIN REAGENTS DIATRON CORPORATION (US) 1991-11-28 WO disclosed
US-5061715-A Useful in treating AIDS and ARC MERRELL DOW PHARMACEUTICALS INC. (US) 1991-10-29 US disclosed
US-4999431-A Reacting A Bromoquinoline Compound With Butyllithium And An N-Methyl-N-Methoxyalkanamide; Intermediates for Quinolyloxazole-2-ones MERRELL DOW PHARMACEUTICALS (US) 1991-03-12 US disclosed
US-4990519-A Antiasthma, hypotensive agents, bronchodilator agents MERRELL DOW PHARMACEUTICALS (US) 1991-02-05 US disclosed
US-4886811-A HYPOTENSIVE AGENTS AND VASODILATORS MERRELL DOW PHARMACEUTICALS (US) 1989-12-12 US disclosed
US-4692515-A BACTERICIDE, ANTICONVULSANT, ANTIHYPOXIA, ANTIPARKINSON, ANTICHOLINERGICS PENNWALT CORPORATION (US) 1987-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 CYP1A2 1131/4885CYP2A6 1385/4885TAAR1 319/4885
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CYP1A2 848/4885CYP2A6 703/4885TAAR1 2099/4885
US-11767334-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CYP1A2 848/4885CYP2A6 703/4885TAAR1 2099/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CYP1A2 848/4885CYP2A6 703/4885TAAR1 2099/4885
US-20040204485-A1 Process of preparing esters and ethers of probucol and derivatives thereof NR3C2, MGLL, GCG CYP1A2 394/4885CYP2A6 355/4885TAAR1 3193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.